Non Chemotherapy Combo Shows Efficacy Against Relapsed CLL

A small clinical trial has demonstrated that four of five patients with relapsed chronic lymphocytic leukemia (CLL) respond to a new therapy that does not involve chemotherapy.

The combination therapy included rituximab (Rituxan) and venetoclax (formerly ABT-199), an inhibitor of the anti-apoptosis protein B-cell lymphoma-2 (BCL-2).

A total of 41 out of 49 patients in the trial met the criteria for having experienced an objective response. Of those, nearly half had complete responses, meaning their disease was in remission afterwards.

The most frequently seen side effect was neutropenia.

Andrew W. Roberts, MD, of the Royal Melbourne Hospital in Australia, reported on the results at the European Hematology Association meeting taking place in Vienna.

"The combination of venetoclax and rituximab is a highly active, non-chemotherapy treatment for patients with relapsed and refractory CLL," he said. "The combination is well tolerated, as we observed no new toxicities as compared with venetoclax monotherapy. We observed minimum residual disease (MRD) in bone marrow in 24 of 49 patients, including 13 patients who achieved a complete response and MRD negativity.”

BCL-2 represents a major apoptosis escape mechanism for CLL-- in other words, BCL-2 allows the cancer cells to avoid programmed cell death. Venetoclax is believed to work by inhibiting BCL-2, which allows for the cell to undergo programmed cell death.

The patients in this trial had a median age of 68 and had a median treatment exposure of two prior therapies. Some patients had as many as five prior therapies.

Ultimately, there was an 84% overall response rate, including complete responses in 20 of 41 responding patients. Three of those 41 patients however have since relapsed.

Source: MedPage Today

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...